© 1983 Oxford University Press
research-article |
Preclinical Toxicology Studies with Acyclovir: Teratologic, Reproductive and Neonatal Tests
Wellcome Research Laboratories 3030 Cornwallis Road, Research Triangle Park, NC 27709
Preclinical Toxicology Studies with Acyclovin Teratologic, Reproductive and Neonatal Tests. Moore, H.L., Jr., Szczech, G.M., Rodwell, D.E., Kapp, R.W., Jr., de Miranda, P. and Tucker, W.E., Jr. (1983).Fundam. Appl Toxicol 3:560–568. Five studies were done to define the potential of Acyclovir (ACV), a new nucleoside analog for antiviral chemotherapy, to produce adverse effects on reproduction and development in laboratory animals. ACV produced no adverse effects when given by gavage to F0 generation mice at 50, 150 and 450 mg/kg/day in a two generation reproduction/fertility study. Some mice were evaluated for teratologic effects and others for postnatal development, including behavior, with negative results. ACV was not embryotoxic and did not increase the incidence of fetal malformations when given by subcutaneous injection to pregnant rats and rabbits at dose levels of 12, 25 and 50 mg/kg/day during the periods of major organogenesis. A comparative LD50 study revealed that 3-day-old rats were not more sensitive to acute toxic effects of ACV than more mature rats. Finally, in a comprehensive multidose toxicity study ACV was given subcutaneously to neonatal rats at 5, 20 and 80 mg/kg/day for 19 consecutive days. There was minimal effect on body weight gain in neonates treated at 20 mg/kg/day and a significant decrease in body weight gain at 80 mg/kg/day. Minimal renal lesions occurred at 80 mg/ kg/ day but no other signs of adverse effects on developing organ systems were observed. Except for decreased body weight gain in neonatal rats treated at 80 mg/kg/day, ACV did not produce adverse effects on mammalian development when tested in a variety of preclinical toxicology studies.